Key facts
- Ordaos’s last known valuation is $110.0M (Nov 2024).
- It has raised $24.5M across 6 recorded rounds; the latest was Seed Round ($338K) in Feb 2025.
- Notable investors include StartX (US), AWS Startups, 2468 Ventures, IAG Capital Partners, SeedFolio — 16 tracked in total.
- Ordaos has filed 6 Form Ds with the SEC since 2022, most recently Apr 2025 ($338K sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Ordaos
Funding rounds
6 roundsAbout Ordaos
Operator of a human-enabled machine-driven drug design company intended for biomedical research and drug discovery. The company's platform provides an artificial intelligence drug discovery pipeline for researchers to develop novel immunotherapies in oncology and chronic inflammatory disease, enabling medical practitioners to deliver safer and more effective treatments than traditional discovery methods.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 25
- Website
- ordaos.bio/
- Ownership
- Privately Held (backing)
Ordaos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ordaos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ordaos in its N-PORT filings yet. We sweep new filings monthly.